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Amongst the recognized classes of naturally occurring antimicrobials, human host
defense peptides are an important group with an advantage (given their source) that
they should be readily translatable to medicinal products. It is also plausible that
truncated versions will display some of the biological activities of the parent peptide,
with the benefit that they are less costly to synthesize using solid-phase chemistry.
The host defense peptide, LL-37, and two truncated mimetics, KE-18 and KR-12,
were tested for their inhibitory effects and antibiofilm properties against Candida
albicans, Staphylococcus aureus, and Escherichia coli, microorganisms commonly
implicated in biofilm-related infections such as ventilator-associated pneumonia (VAP).
Using in silico prediction tools, the truncated peptides KE-18 and KR-12 were
selected for minimum inhibitory concentration (MIC) and antibiofilm testing on the
basis of their favorable cationicity, hydrophobic ratio, and amphipathicity compared
with the parent peptide. Two methods were analyzed for determining peptide
efficacy against biofilms; a crystal violet assay and an XTT [2,3-bis-(2-methoxy-
4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] assay. The biocidal activities
(measured by MIC) and antibiofilm activities (measured by a crystal violet assay)
appeared to be independent. LL-37 had no biocidal action against C. albicans
(MIC > 250 µg/ml) but significant effects in both biofilm-prevention and biofilm-
inhibition assays. KE-18 and KR-12 yielded superior MIC values against all three
microorganisms. Only KE-18 had a significant effect in the biofilm-prevention assay,
which persisted even at sub-MICs. Neither of the truncated peptides were active
in the biofilm-inhibition assay. KE-18 was shown to bind lipopolysaccharide as
effectively as LL-37 and to bind lipoteichoic acid more effectively. None of the
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peptides showed hemolytic activity against human erythrocytes at the concentrations
tested. KE-18 should be considered for further development as a natural peptide-
derived therapeutic for prevention of multi-species biofilm-related infections such
as VAP.
Keywords: antimicrobial peptide, biofilm, human, LL-37, KE-18
INTRODUCTION
The continual challenge to provide new approaches to
combat antimicrobial resistance has prompted a resurgence
of interest in non-conventional treatments for infection
(Czaplewski et al., 2016). Novel therapeutic strategies are
particularly relevant for medical device–related infections,
such as ventilator-associated pneumonia (VAP) because of the
potential for coating/treating devices (such as endotracheal
tubes) with antimicrobials to prevent biofilm formation before
insertion in vivo. Interventions of this type could, therefore,
preclude pathogenic microorganisms becoming established
in endotracheal tube biofilms, which are known to develop
rapidly after intubation (Danin et al., 2014). The species
diversity associated with VAP (Adair et al., 1999; Azoulay et al.,
2006; Cairns et al., 2011) and the restricted potential for their
eradication using conventional antibiotic treatments further
emphasizes the need to investigate alternative therapeutic
approaches for biofilm-prevention.
Antimicrobial peptides (AMPs) are naturally occurring
antimicrobial agents, found in both the animal and plant
kingdoms, with non-specific, immediate activities against a broad
spectrum of microorganisms (Sang and Blecha, 2008). Several
AMPs have been shown to have better antibiofilm activities
than conventional antibiotics, owing to their rapid and broad-
spectrum biocidal mechanisms, which appear to be effective
against cells with low metabolic activities (Jorge et al., 2012). In
addition, AMPs have also been shown to possess non-biocidal
antibiofilm activities. For example, covalent immobilization
of the AMP nisin onto a carbon-based surface was found
to prevent the initial attachment of Staphylococcus aureus
at concentrations below its minimal inhibitory concentration
(MIC) (Qi et al., 2011). The 37-amino acid human cathelicidin,
LL-37, has also been shown to have biofilm-prevention activities
that are independent of its biocidal effects (Overhage et al.,
2008).
In terms of generating novel peptides, both combinatorial
(He et al., 2010) and rationally designed (Ashby et al., 2016)
approaches have been used successfully to produce novel peptide
libraries for biological screening. However, much remains to
be learned about the exact nature of the structure-sequence-
activity relationships that govern antimicrobial bioactivity, and
thus, it continues to be challenging to design and generate
functional AMPs de novo. Optimization of selected natural
peptides, including peptide fragments and altered sequences
based on natural AMPs, has facilitated discovery of novel
short AMPs and improved their activity, providing excellent
leads for therapeutic intervention. In view of this, our research
group and others have used truncation of naturally occurring
AMPs from human (Lundy et al., 2008), animal (Jittikoon
et al., 2015), plant (Remuzgo et al., 2014), and bacterial (Zhou
et al., 2015) sources as templates for the design of novel
antimicrobials. Truncation of natural AMPs not only takes
advantage of their evolutionary bioactivity but also advances
them toward peptide therapeutics, which should ideally be short
and compositionally simple, in order to minimize solid-phase
synthesis costs.
Evidence from structure–activity relationship studies has
demonstrated the importance of key characteristics such as
peptide hydrophobicity and cationicity, but there are few
comprehensive rules for natural peptide truncation, since the
amino-terminal, mid-region, and carboxy-terminal sections of
individual peptides may have variable structural features and
resulting biological activities. Thus, it is important to utilize
in silico prediction packages to guide peptide truncation in
order to facilitate retention/enhancement of bioactivity with
lower production costs. Several research groups have shown that
the antibacterial activity of LL-37 resides in its mid-region (Li
et al., 2006; Nell et al., 2006; Kanthawong et al., 2012) and thus
truncation of this peptide could have particularly important cost
benefits, given the expense of synthesizing a 37-mer peptide
for therapeutic use. Stabilized LL-37 (D-enantiomer) as well
as truncated mimetics of LL-37 have previously been shown
to have antibiofilm activity against Pseudomonas aeruginosa
(Dean et al., 2011; Nagant et al., 2012), but there is no
information on the bioactivity and biofilm-prevention/inhibitory
properties of LL-37 and truncated mimetics against other lung
pathogens.
In the current work, we studied the bioactivity and
biofilm-prevention/inhibitory properties of LL-37, and two
truncated peptides, KE-18, and KR-12 against Candida
albicans, Staphylococcus aureus, and Escherichia coli. All
three microorganisms have recently been implicated in VAP
(Hellyer et al., 2015), and C. albicans is of particular interest
because fungal–bacterial interactions have the potential to
modulate antibiotic efficacy (Harriott and Noverr, 2009, 2010),
which could compromise conventional antibiotic treatment of
multi-species infections.
In this study, truncation of LL-37 was shown to yield
superior MIC values for KE-18 and KR-12 against all three
microorganisms tested, but only KE-18 proved efficacious in
the biofilm-prevention assay, and neither of the truncated
peptides were active in the biofilm-inhibition assay. Furthermore,
truncation was shown to retain or improve indirect antimicrobial
activities such as lipopolysaccharide (LPS)- and lipoteichoic acid
(LTA)-binding efficacy. Truncated mimetics of LL-37, and in
particular KE-18, should thus be considered for prevention of
multi-species biofilm-related infections such as VAP.
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MATERIALS AND METHODS
Microorganism Strains
Escherichia coli ATCC 25922 (LGC Standards, Middlesex, UK)
and S. aureus NCTC 6571 (Public Health England, Salisbury,
UK) were maintained on Colombia blood agar plates (Fannin,
Galway, Ireland), and C. albicans NCTC 3179 was maintained
on Sabouraud agar plates, prepared in-house using Sabouraud
dextrose liquid media (Oxoid, Thermo Fisher, Hampshire, UK)
and agarose (Helena Biosciences Europe, Tyne and Wear, UK).
Peptides
LL-37 was supplied by Innovagen (Lund, Sweden). The truncated
peptides KE-18 and KR-12 were custom synthesized by EZBiolab
(Carmel, IN, USA) (Table 1).
Radial-diffusion Assay for MIC
Determination
A double-layer radial-diffusion assay was performed as
previously described (McLean et al., 2013) to determine the
MICs of LL-37, KE-18 and KR-12 against C. albicans, S. aureus,
and E. coli. The underlay gel (10 ml) consisted of 1% (w/v)
agarose containing approximately 4 × 105 yeast cells or
5× 106 bacterial cells. Wells (2.5 mm in diameter) were punched
in the agar, and 3 µl of peptide (0–250 µg/ml) was added prior
to the addition of a nutrient-rich agarose over-layer (McLean
et al., 2013). The plates were incubated for 18 h at 37◦C and
stained with a dilute solution of Coomassie brilliant blue R-250
as previously described (Lehrer et al., 1991; McLean et al., 2013).
The antimicrobial activities were expressed as MICs, determined
as the x intercept obtained from the relationship between
radial-diffusion units versus log10 peptide concentration (Lehrer
et al., 1991). The mean MICs were calculated from three replicate
experiments.
Inoculum Preparation for Biofilms
An overnight culture of C. albicans was grown in yeast extract
peptone dextrose (YPD) broth (US Biological Life Sciences,
Marblehead, MA, USA). Following centrifugation and washing in
phosphate-buffered saline (PBS), the pellet was re-suspended in
Roswell Park Memorial Institute (RPMI) 1640 medium (Cellgro
Mediatech Inc., Manassas, VA, USA) and diluted to an optical
density of 0.05 (600 nm;∼1.0× 106 cells/ml) (Pierce et al., 2008).
Inoculum preparations for S. aureus and E. coli were grown
and diluted in brain-heart infusion (BHI) broth (Oxoid, Thermo
Fisher, Hampshire, UK) to an optical density of 0.02 (600 nm;
∼5.0× 106 cells/ml) (Wang et al., 2007; Müsken et al., 2010).
Biofilm-Prevention Assay
A biofilm-prevention assay was used to evaluate the ability
of the peptides LL-37, KE-18, and KR-12 to prevent or
reduce biofilm formation. Peptides were added to the inoculum
preparations before addition to the wells of sterile, flat-bottomed,
96-well, microtiter plates (Nunc R©, Sigma–Aldrich, Ayrshire,
UK). Peptides were tested in the biofilm-prevention assay
at either ×2 or at ×0.5 their MIC against the planktonic
microorganism (Table 2). The only exception was LL-37, which
was ineffective against C. albicans in the radial-diffusion assay,
and thus, a concentration of twice the MIC of LL-37 against
S. aureus was selected (i.e., 38.6 µg/ml; Table 2). Plates were
then incubated at 37◦C for 24 h to allow biofilm formation.
Wells were washed three times with 200 µl PBS to facilitate
removal of planktonic cells before quantification by the crystal
violet assay or 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT) assay.
Biofilm-inhibition Assay
A biofilm-inhibition assay was used to evaluate the ability of LL-
37, KE-18, and KR-12 to disrupt or inhibit the maturation of early
biofilms. An overnight culture of microorganisms was prepared
and diluted as described above. An initial biofilm was allowed
to form for 4 hours, which has previously been shown to be
sufficient for microbial attachment to plastic surfaces (Coenye
et al., 2007; Pierce et al., 2008). Wells were then washed three
times with 200 µl PBS to facilitate removal of planktonic cells
before addition of peptides (at×2 their MIC against each species
except for LL-37 against C. albicans, as outlined above) in broth
(100 µl). Plates were then incubated for further 24 h to allow
biofilm maturation. Wells were washed, as outlined above, prior
to biofilm quantification by the crystal violet assay or XTT assay.
Crystal Violet Assay
The crystal violet assay was used to quantify the total biomass
of biofilms, including cells and the extracellular matrix (Li et al.,
2003). After the final washing step to remove planktonic cells,
the biofilm was fixed with methanol and stained with crystal
violet (Clin-Tech Ltd, Guildford, UK). Crystal violet dye that had
bound to biofilms was released by adding 160 µl of 33% acetic
acid to each well, and optical density was measured at 570 nm
using a microtiter plate reader (GENios, Tecan, Männedorf,
Switzerland).
XTT Assay
XTT was used to measure the metabolic activity of cells within
the biofilm. It was prepared as a saturated solution of 0.5 g/L
in sterile RPMI, filter sterilized and stored at −70◦C protected
TABLE 1 | Amino acid sequences, overall net charge, and hydrophobic ratios of LL-37, KE-18, and KR-12 [charge and hydrophobic ratios were
determined using the “calculation and prediction” feature of the Antimicrobial Peptide Database (http://aps.unmc.edu/AP/main.php)].
Peptide Sequence Charge Molecular mass Hydrophobic ratio
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES +6 4493.33 35%
KE-18 KEFKRIVQRIKDFLRNLV +4 2302.80 44%
KR-12 KRIVQRIKDFLR +4 1571.93 41%
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from light. 10 mM Menadione (Sigma-Aldrich, Ayrshire, UK)
stock solution was prepared in 100% acetone and stored at
−70◦C. Menadione stock solution was added to XTT solution
to make a XTT/menadione working solution containing 1 µM
menadione; 100 µl XTT/menadione working solution was then
added to prewashed biofilm well and negative control wells.
Plates were incubated at 37◦C for 2 h in the dark. A total of
80 µl of supernatant was then removed from each well for
measurement of optical density at 490 nm (Pierce et al., 2008)
using a microtiter plate reader (GENios, Tecan, Männedorf,
Switzerland).
Confocal Imaging of Biofilms
Biofilms for confocal imaging were grown on transparent
ThinCert inserts (0.4 µm diameter) placed in six-well plates
(Greiner Bio-One, Frickenhausen, Germany). KE-18 (×2 MIC)
was added to the S. aureus inoculum preparations (1 ml
in BHI, prepared as above) before addition to the ThinCert
inserts. A further 1 ml BHI was also added to the bottom
of wells during biofilm formation on the insert at 37◦C
for 24 h. The insert was washed three times with PBS to
facilitate removal of planktonic cells and then stained with the
LIVE/DEAD R© BacLight BacterialTM Viability Kit, (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
The insert was then viewed by confocal laser scanning
microscopy (LEICA-SP5 confocal with Leica Application Suite
Advanced Fluorescence software) at×100 magnification.
LPS- and LTA-binding Assays
Escherichia coli LPS (Sigma–Aldrich, Ayrshire, UK) and S. aureus
LTA (InvivoGen, San Diego, CA, USA) were biotinylated with
biotin (long arm) hydrazide (Vector Laboratories, Peterborough,
UK) using the biotin-labeling method outlined for glycoproteins
as described by the manufacturer.
Peptide binding to biotinylated LPS was determined as
previously described (McLean et al., 2013). Briefly, Greiner high-
binding 96-well plates were coated with 100 µl of LL-37, KE-
18, or KR-12 (6.25 µg/ml) in Voller’s buffer (26 mM Na2CO3,
23 mM NaHCO3, pH 9.6) overnight at 37◦C. Plates were washed
three times with Dulbecco’s PBS containing 0.05% Tween-20
(PBST) and blocked in PBST containing 1% (w/v) BSA for 1 h
at room temperature. After washing three times with PBST,
100 µl of 1 ng/µl biotinylated E. coli LPS in PBS was added
to each well and incubated at room temperature for 3 h with
gentle agitation. Following three washes with PBST, detection
of bound biotinylated LPS was achieved by adding 100 µl of
streptavidin–horseradish peroxidase (BioLegend, London, UK),
diluted 1:2000 in PBST for 30 min at room temperature.
Following washing steps as above, peroxidase activity was
detected with 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic
acid) (ABTS; Invitrogen, Carlsbad, CA, USA; 100 µl/well)
at 405 nm using a microtiter plate reader (GENios, Tecan,
Männedorf, Switzerland).
Peptide binding to biotinylated LTA was determined as
outlined above except that biotinylated LTA (1 ng/µl) was used
in place of biotinylated LPS.
Hemolytic Assay
The hemolytic assay was employed to determine potential peptide
cytotoxicty against human erythrocytes (collected with ethical
permission). Briefly, LL-37, KE-18, and KR-12 (0–175 µg/ml;
100 µl in PBS) were tested for their ability to release hemoglobin
from an 8% suspension of fresh human erythrocytes (100 µl).
One percent Triton X-100 (100 µl; Sigma–Aldrich) and 100 µl
PBS were used as positive and negative controls, respectively.
Samples and controls were incubated at 37◦C for 1 h and
then centrifuged for 5 min before reading the absorbance
of the supernatant at 450 nm in a microtiter plate reader
(Tecan GENios). Peptides were analyzed in triplicate in three
independent assays. The % hemolysis was calculated using the
equation:
% hemolysis = (Abssample − Absnegative control)
(Abspositive control − Absnegative control)× 100
(1)
Statistical Analysis
Results for the antibiofilm properties of LL-37, KE-18, and KR-
12 against C. albicans, S. aureus, and E. coli represent an average
of three independent experiments and were subject to analysis
by one-way ANOVA followed by Tukey’s post hoc correction
for multiple comparisons. Results for the LPS- and LTA-binding
efficacies of LL-37, KE-18, and KR-12 represent an average of
three independent experiments and were also analyzed by one-
way ANOVA followed by Tukey’s post hoc correction for multiple
comparisons.
RESULTS
Using in silico prediction software, truncation of LL-37 was
shown to improve the hydrophobic ratio but decrease the
charge of both KE-18 and KR-12 (Table 1). Helical wheel
projection of LL-37, KE-18, and KR-12 showed that the truncated
peptides displayed superior amphipathic helixes compared with
the parent peptide (Figure 1). Truncation of LL-37 to KE-18
and KR-12 improved antimicrobial activity against C. albicans,
S. aureus, and E. coli, as determined by radial-diffusion assays
(Table 2).
Quantification of biofilm biomass with the crystal violet
assay (Figure 2) showed that LL-37 had significant efficacy in
preventing biofilm formation by C. albicans, S. aureus, and E. coli
and was also effective against early biofilms of C. albicans and
E. coli but was unable to inhibit early biofilms of S. aureus
(Figure 2). KE-18 showed significant activity against C. albicans
and S. aureus in the biofilm-prevention assay but not in any
of the biofilm-inhibition assays (Figure 2). KR-12 showed no
antibiofilm properties against C. albicans, S. aureus, or E. coli
in either biofilm-prevention or -inhibition assays (Figure 2).
When the efficacy of the AMP family was investigated using the
XTT metabolic assay (Figure 3), the results showed considerable
differences to those reported with the crystal violet assay, with LL-
37 and KE-18 preventing biofilm formation against C. albicans
only (Figure 3).
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FIGURE 1 | Helical wheel projections of LL-37, KE-18, and KR-12. Helical wheels were drawn using the EMBOSS pepwheel program
(http://emboss.bioinformatics.nl/cgi-bin/emboss/pepwheel). Aliphatic residues (hydrophobic) are marked with squares, hydrophilic residues are marked with
diamonds, positively charged residues are marked with octagons, and the remaining amino acids are unmarked. KE-18 and KR-12 show superior amphipathicity
(hydrophobic residues confined to one face of the helix) compared with the parent LL-37 peptide.
TABLE 2 | Minimum inhibitory concentration (MIC) values of LL-37, KE-18,
and KR-12 against Candida albicans, Staphylococcus aureus, and
Escherichia coli.
Microorganism MIC (µg/ml)
LL-37 KE-18 KR-12
C. albicans, NCTC 3179 >250 84 (±1) 5 (±2)
S. aureus, NCTC 6571 19.3 (±5) 7.2 (±0.6) 8.4 (±6.3)
E. coli, ATCC 25922 9.8 (±5.4) 2.1 (±1) 2.1 (±0.7)
MIC values are the mean values (±SD) calculated from three individual radial-
diffusion assays.
Given the activity of LL-37 and KE-18 in biofilm-prevention,
both peptides were also tested to determine their antibiofilm
activities at sub-MICs (Figure 4). LL-37 and the truncated
peptide KE-18 were shown to be efficacious against C. albicans
and S. aureus biofilms at sub-MIC (Figure 4), but neither peptide
displayed sub-MIC antibiofilm activity against E. coli. Confocal
imaging of KE-18-treated biofilms (Figure 5) showed that KE-
18 appeared to prevent attachment of S. aureus [as shown by
a decrease in green staining (live)] following treatment rather
than by direct killing [no increase in red staining (dead) with
KE-18 treatment]. Both KE-18 and KR-12 were shown to retain
the LPS-binding activity of LL-37 (Figure 6). Furthermore, KE-
18 displayed significantly enhanced LTA-binding activity, while
KR-12 retained the weak LTA-binding activity of the parent
peptide (Figure 7). All peptides showed minimal activity in the
hemolytic assay against human erythrocytes, even at the highest
concentration of 175 µg/ml tested (Table 3).
DISCUSSION
In the current study, we focused on truncation of the naturally
occurring AMP, LL-37, to KE-18 and KR-12 and showed that
KE-18 retained planktonic and antibiofilm efficacy against the
VAP-associated microorganisms C. albicans, S. aureus, and
E. coli. The antimicrobial activity of the majority of AMPs
is believed to depend on a combination of interdependent
structural parameters including cationicity, hydrophobicity,
and amphipathicity (Yeaman and Yount, 2003). In the current
work, the reduction in cationicity compared with LL-37
may have been offset by a slightly higher hydrophobic ratio
for KE-18 and KR-12. Additionally, it is recognized that
amphipathicity (separation of charged groups from hydrophobic
residues on the peptide) promotes interaction with negatively
charged microbial membranes and subsequent penetration
into the hydrophobic lipid bilayer (Fernandez-Vidal et al.,
2007). The peptide amphipathicity of KE-18 and KR-12,
visualized by helical wheel projection, revealed that the
truncated peptides displayed superior amphipathic helixes
to LL-37, which may have contributed to their enhanced
antimicrobial activity, as determined by radial-diffusion
assay.
In previous studies, LL-37 was found to possess unique
antibiofilm activities [against P. aeruginosa (Overhage et al.,
2008), Staphylococcus epidermidis (Hell et al., 2010), and
Francisella novicida (Amer et al., 2010)]. However, only one study
has previously focused on the antibiofilm activities of LL-37-
derived peptides generated by truncation of both the N- and
C-terminals (against Acinetobacter baumannii; Feng et al., 2013).
Our observations on the in vitro efficacy of LL-37, KE-18, and
KR-12 against C. albicans, S. aureus, and E. coli biofilms provide
further support for the concept that the antibiofilm activities of
AMPs are generally independent of their antimicrobial activities
against planktonic cells (Overhage et al., 2008).
Several databases have been established to collate AMP
sequences. The novel antibiofilm properties of LL-37, KE-18,
and KR-12 reported here will be added to a recently established
database specifically for biofilm-active AMPs (BaAMPs; Di Luca
et al., 2015). Further investigation, however, will be required
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FIGURE 2 | Biofilm-prevention and biofilm-inhibition (of pre-formed biofilms) for LL-37, KE-18, and KR-12 against (A) Candida albicans,
(B) Staphylococcus aureus, and (C) Escherichia coli, measured using the crystal violet assay. One-way ANOVA followed by Tukey’s post hoc correction for multiple
comparisons, N = 3 independent experiments, three replicates in each (∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001).
to determine which features of the LL-37 parent molecule
specifically contribute to its antibiofilm activities. In particular,
it will be of interest to determine whether the amphipathic
helix portion of the parent molecule, needed for interaction
with bacterial membranes (Wang et al., 2012), is necessary
for antibiofilm activity. Interestingly, both KE-18 and KR-12
are devoid of the first six amino acids of LL-37, which have
previously been shown to contribute to the cytotoxicity of the
parent peptide (Nagant et al., 2012). In the current study, peptide
hemolytic activity against human erythrocytes was tested up to
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FIGURE 3 | Biofilm-prevention and biofilm-inhibition (of pre-formed biofilms) for LL-37, KE-18, and KR-12 against (A) C. albicans, (B) S. aureus, and (C)
E. coli, measured using the XTT assay. One-way ANOVA followed by Tukey’s post hoc correction for multiple comparisons, N = 3 independent experiments, three
replicates in each (∗∗∗p < 0.001).
a concentration of 175 µg/ml [so as to exceed the X2 MIC
value for KE-18 against C. albicans (168 µg/ml)]. There was
minimal hemolysis (<5%) of human erythrocytes even at the top
concentration, and many of the peptides were active at much
lower concentrations (<50 µg/ml), which could enhance their
therapeutic potential.
The formation of biofilms on endotracheal tubes is
considered a reservoir for respiratory pathogens in VAP
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FIGURE 4 | Biofilm-prevention for LL-37 and KE-18 at sub-minimum
inhibitory concentration (MIC) against (A) C. albicans, (B) S. aureus, and
(C) E. coli, measured using the crystal violet assay (∗p < 0.05; ∗∗∗p < 0.001;
∗∗∗∗p < 0.0001).
patients (Pneumatikos et al., 2009), and thus, the prevention
of biofilm formation by LL-37 and KE-18 could potentially
serve to limit respiratory infections. Indeed, it is recognized
that novel antibiofilm therapeutics need not fully eradicate
FIGURE 5 | Confocal imaging of live/dead-stained S. aureus biofilms
[left, green channel (live); middle, red channel (dead); right, merged
green and red channels]. (A) Untreated S. aureus biofilm and
(B) KE-18-treated S. aureus biofilm.
FIGURE 6 | Binding of LL-37, KE-18, and KR-12 to biotinylated E. coli
lipopolysaccharide (LPS). One-way ANOVA followed by Tukey’s post hoc
correction for multiple comparisons showed no significant difference in LPS
binding between LL-37 and its truncated mimetics.
biofilms but rather, by serving to reduce or delay their
formation, they could allow secondary immune responses a
better chance of combating potential infections (Singh et al.,
2002). It has been previously reported that at sub-inhibitory
concentrations, some conventional antibiotics (including
aminoglycosides, fluoroquinolones, and tetracycline) can
actually stimulate bacterial biofilm formation on medical
devices (Hoffmann et al., 2005; Linares et al., 2006). Thus,
it was important to show that LL-37, KE-18, and KR-
12 had no such effects on the biofilms tested. In fact,
both LL-37 and KE-18 continued to exhibit significant
sub-MIC antibiofilm activity against C. albicans and
S. aureus.
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FIGURE 7 | Binding of LL-37, KE-18, and KR-12 to biotinylated
S. aureus lipoteichoic acid (LTA). One-way ANOVA followed by Tukey’s
post hoc correction for multiple comparisons showed significantly enhanced
LTA binding for KE-18 compared with LL-37 (∗∗∗p < 0.001).
TABLE 3 | Hemolytic activities of LL-37, KE-18, and KR-12 against human
erythrocytes.
Peptide/positive control Concentration Average % hemolysis
LL-37 175 µg/ml 4.47 (±0.35)
KE-18 175 µg/ml 1.17 (±0.18)
KR-12 175 µg/ml 0.45 (±0.10)
Triton X-100 1% (v/v) 100
% hemolysis is the mean value (±SD) calculated from three individual hemolytic
assays.
The antibiofilm properties of novel antimicrobials have
previously been reported using both the crystal violet assay
(Overhage et al., 2008) and the XTT assay (Martinez and
Casadevall, 2006), and indeed, the use of more than one
bioassay has recently been recommended (Ramage, 2016). It
is acknowledged that assays utilizing different mechanisms for
biofilm assessment may produce conflicting results. Furthermore,
it is recognized that antimicrobial treatments can increase
metabolic activity in the absence of increased biofilm as a result
of protease secretion or the pumping out antimicrobials (Zasloff,
2002). Our results for the peptide-treated wells in the XTT assay
concur with increased metabolic activity rather than increased
cell numbers, since on visual inspection, peptide-treated biofilms
in both the crystal violet and XTT assays appeared similar.
Given that naturally occurring peptides have important
roles in innate host defense (Diamond et al., 2009), it is
important to consider potential indirect effects such as their
immunomodulatory actions. We showed that KE-18 and KR-
12 retained the LPS-binding activity of LL-37 and, furthermore,
that truncation of LL-37 to KE-18 significantly improved its
ability to bind LTA. Thus, by effectively binding both LPS and
LTA, KE-18 could be particularly important in reducing TLR-2
and TLR-4 stimulation, thereby limiting host pro-inflammatory
responses.
In addition to its antimicrobial activities, LL-37 has
emerged as both a positive and negative modulator of
tumor growth/metastasis depending on the tumor type (Wu
et al., 2010). In vitro studies have shown that the anticancer
activity of LL-37 resides along with its antimicrobial activity
in the central amphipathic helix (Li et al., 2006). Indeed,
fragments of LL-37, including a 25 amino peptide, IG-25
(corresponding to amino acids 13–37 in the parent LL-37
peptide) showed anticancer activity against human cancer
cell lines in vitro (Li et al., 2006). It is tempting to speculate
that KE-18 and KR-12 may also exhibit anticancer activity
given that their sequences fall within the IG-25 peptide;
however, further work will be required to fully investigate this
potential.
CONCLUSION
In conclusion, we show, for the first time, the antimicrobial
and antibiofilm properties of LL-37 and two truncated mimetics,
KE-18 and KR-12, against the VAP-related microorganisms
C. albicans, S. aureus, and E. coli. In light of the challenge
of antimicrobial resistance, non-conventional treatments that
may attenuate infection while conserving systemic antibiotics
used for treatment, such as truncated AMPs, merit attention.
In particular, KE-18 is promising in view of its favorable
immunomodulatory and antibiofilm activities. Recent biofilm
peptide immobilization approaches (Gao et al., 2011; Lim
et al., 2015) offer exciting possibilities for the prevention
of biofilm infections on medical devices and provide proof
of concept for immobilizing antibiofilm peptides such as
KE-18.
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